Our finding of ZFHX3 as an indispensable factor for ERβ function in this study suggests that the status of ZFHX3 needs to be considered when restoring or enhancing ERβ activity via its agonists for the treatment of prostate cancer. Here, ESR2 is linked to prostate carcinoma.